LUMO — Lumos Pharma Share News
0.000.00%
Last trade - 00:00- $37.41m
- $23.89m
- $2.05m
NASDAQ RESUMED AT 09:37 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:31 AM
Brief: Lumos Pharma Announces OraGrowtH212 Trial Of LUM-201 In PGHD Is Open For Enrollment
Brief: Lumos Pharma Reports Qtrly Loss Per Share Of $1.04
Lumos Pharma Inc expected to post a loss of 87 cents a share - Earnings Preview
Brief: Lumos Pharma To Present New Data On Three PGHD Patients Treated With Lum-201 In Prior Phase 2 Study
Brief: Lumos Pharma Announces Retirement Of Carl Langren And Names Lori Lawley Chief Financial Officer In Planned Succession
U.S. RESEARCH ROUNDUP- Coca-Cola, Lam Research, Valvoline
Brief: Lumos Pharma Reports Full Year 2020 Financial Results
Brief: Data Supporting Use Of Predictive Enrichment Markers For Lumos Pharma’S Lum-201 Therapy In Clinical Trials
Brief: Lumos Pharma Enters Into Controlled Equity Offering Sales Agreement Up To $50 Mln Of Shares Of Co's Common Stock
Brief: Lumos Pharma Reports Initiation Of Phase 2B OraGrowtH210 Trial
U.S. RESEARCH ROUNDUP-Domtar, Hilton Worldwide Holdings, Pegasystems
Brief: Lumos Pharma Reports Qtrly Loss Per Share $0.65
Brief: Lumos Pharma Files For Resale Of Up To 4.15 Mln Shares
Brief: Lumos Pharma Files For Shelf Of Up To 4.15 Mln Shares By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP- Apache, Bloomin' Brands, MEI pharma
Brief: Lumos Pharma Reports Q1 Loss Per Share Of $0.14
Brief: Lumos Pharma Says Has Had To Re-Evaluate Timing Of Phase 2B Clinical Trial For Product Candidate LUM-201